Literature DB >> 25495491

Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.

Dawn L Hershman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25495491     DOI： 10.1056/NEJMe1413164

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Analysis of Adjuvant Endocrine Therapy in Practice From Electronic Health Record Data of Patients With Breast Cancer.

Authors:  Morgan Harrell; Daniel Fabbri; Mia Levy
Journal:  JCO Clin Cancer Inform       Date:  2017-11

2.  Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Authors:  Karin Ribi; Weixiu Luo; Jürg Bernhard; Prudence A Francis; Harold J Burstein; Eva Ciruelos; Meritxell Bellet; Lorenzo Pavesi; Ana Lluch; Marilena Visini; Vani Parmar; Carlo Tondini; Pierre Kerbrat; Antonia Perelló; Patrick Neven; Roberto Torres; Davide Lombardi; Fabio Puglisi; Per Karlsson; Thomas Ruhstaller; Marco Colleoni; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Meredith M Regan; Gini F Fleming
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

Review 3.  Clinical utilities of aromatase inhibitors in breast cancer.

Authors:  Saranya Chumsri
Journal:  Int J Womens Health       Date:  2015-05-06

4.  Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.

Authors:  Tara Sanft; Bilge Aktas; Brock Schroeder; Veerle Bossuyt; Michael DiGiovanna; Maysa Abu-Khalaf; Gina Chung; Andrea Silber; Erin Hofstatter; Sarah Mougalian; Lianne Epstein; Christos Hatzis; Cathy Schnabel; Lajos Pusztai
Journal:  Breast Cancer Res Treat       Date:  2015-11-14       Impact factor: 4.872

5.  Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Authors:  Kelly-Anne Phillips; Meredith M Regan; Karin Ribi; Prudence A Francis; Fabio Puglisi; Meritxell Bellet; Simon Spazzapan; Per Karlsson; Daniel R Budman; Khalil Zaman; Ehtesham A Abdi; Susan M Domchek; Yang Feng; Karen N Price; Alan S Coates; Richard D Gelber; Paul Maruff; Frances Boyle; John F Forbes; Tim Ahles; Gini F Fleming; Jürg Bernhard
Journal:  Br J Cancer       Date:  2016-04-19       Impact factor: 7.640

6.  Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.

Authors:  Jennifer H Jordan; Ralph B D'Agostino; Katherine Ansley; Emily Douglas; Susan Melin; Steven Sorscher; Sujethra Vasu; Sung Park; Anuj Kotak; Paul A Romitti; Nathanial S O'Connell; William G Hundley; Alexandra Thomas
Journal:  JNCI Cancer Spectr       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.